CFTR corrector C17 rescues defective SERCA1 in bovine pseudomyotonia: a potential therapy for Brody myopathy
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddaf142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Eylem E Akyürek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biomedicine and Food Science, University of Padova, viale dell'Università 16, Legnaro 35020, Padova, Italy. Hauptthemen laut MEDLINE: Sarcoplasmic Reticulum Calcium-Transporting ATPases, Cystic Fibrosis Transmembrane Conductance Regulator, Myopathies, Structural, Congenital. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian MIUR, Association Françoise contre les Myopathies, AFM.
Abstract (Originalsprache)
Brody myopathy is an ultra-rare autosomal recessive inherited disorder that impairs skeletal muscle function in humans. It is caused by deficiency of the Sarco(Endo)plasmic reticulum Ca2+-ATPase isoform1 (SERCA1), arising from defects, mainly missense mutations, in the ATP2A1 gene. At present, neither specific therapy, nor mouse model exists for Brody myopathy. Bovine pseudomyotonia (PMT) is a very rare skeletal muscle disorder. As Brody myopathy, it is an autosomal recessive inherited disorder caused by missense variants in the atp2a1 gene. Most mutations generate proteins corrupted in proper folding that although catalytically active, were ubiquitinated and prematurely degraded by the ubiquitin-proteasome system, thus sharing with Cystic Fibrosis the same pathogenetic mechanism. Bovine PMT, despite unconventional, is currently the unique mammalian model of Brody disease. In this study, we show that CFTR correctors, particularly C17, successfully rescue SERCA1 mutants both in vitro and in vivo models. Our findings suggest that CFTR correctors may be a potential innovative pharmacological approach addressing Brody patients in which mutated SERCA1 retains its activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biomedicine and Food Science, University of Padova, viale dell'Università 16, Legnaro 35020, Padova, Italy.
- Clinic for Ruminants, Vetsuisse Faculty, University of Bern, Länggassstrasse 120, Bern 3012 Switzerland.
- Institute of Genetics, Vetsuisse Faculty, University of Bern, Bremgartenstrasse 109A, Bern 3012 Switzerland.
- Department of Biomedical Sciences, University of Padova, via Ugo Bassi 58/b, Padova 35131, Italy.
- Evotec, via Alessandro Fleming 4, Verona 37135, Italy.
- Department of Veterinary Medical Sciences, University of Bologna, via Tolara di Sopra 43, Ozzano Emilia 40064, Bologna, Italy.
ORCID-Profile: Dorianna Sandonà, Roberta Sacchetto
Förderung
- Italian MIUR
- Association Françoise contre les Myopathies
- AFM
- Fondazione Cassa di Risparmio di Bologna CARISBO
- Italian Telethon
- Muscular Dystrophy Association
Zitieren
APA
Akyürek, E. E., Jacinto, J. G. P., Iori, S., Bianchini, E., Bolcato, M., Costa, R., Giantin, M., Carotti, M., Dacasto, M., Cenacchi, G., Sandonà, D., Gentile, A., & Sacchetto, R. (2025). CFTR corrector C17 rescues defective SERCA1 in bovine pseudomyotonia: a potential therapy for Brody myopathy. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf142
Vancouver
Akyürek EE, Jacinto JGP, Iori S, Bianchini E, Bolcato M, Costa R, et al. CFTR corrector C17 rescues defective SERCA1 in bovine pseudomyotonia: a potential therapy for Brody myopathy. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf142
BibTeX
@article{Akyrek2025,
author = {Akyürek, Eylem E and Jacinto, Joana Gonçalves Pontes and Iori, Silvia and Bianchini, Elisa and Bolcato, Marilena and Costa, Roberta and Giantin, Mery and Carotti, Marcello and Dacasto, Mauro and Cenacchi, Giovanna and Sandonà, Dorianna and Gentile, Arcangelo and Sacchetto, Roberta},
title = {CFTR corrector C17 rescues defective SERCA1 in bovine pseudomyotonia: a potential therapy for Brody myopathy},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddaf142}
}
EUVIMED